Interstitial Lung Disease Trajectories in Patients With Systemic Sclerosis

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Apr 19, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how interstitial lung disease (ILD) develops in patients with systemic sclerosis (SSc), a disease that affects the skin and internal organs. ILD is a serious condition that occurs in about half of SSc patients and is a leading cause of death. The researchers want to learn more about the different ways ILD can progress over time, which can vary from stable to fast worsening. By studying these patterns, they hope to create better tools to predict which patients are at higher risk of having their condition worsen, helping to guide treatment.

To participate in this study, individuals must have a confirmed diagnosis of systemic sclerosis and show signs of interstitial lung disease through specific imaging tests. They should also have had lung function tests when they were diagnosed and at least one follow-up test. The trial is currently recruiting participants of all genders, aged 65 to 74. If eligible, participants can expect to be closely monitored over time, providing valuable information that could improve care for others with similar conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with systemic sclerosis according to 2013 ACR/EULAR criteria
• • Patients with interstitial lung disease on HRCT chest
• • Patients with PFT at ILD diagnosis and at least 1 PFT evaluation during follow-up
• Exclusion Criteria:
• • Patients with an alternative diagnosis of SSc-associated ILD (silicosis, sarcoidosis, lung cancer or other significant lung abnormalities)